| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.0M | — | -49.5% |
| SG&A Expense | $2.6M | — | -11.1% |
| Operating Income | -$5.6M | — | +36.8% |
| Net Income | -$5.3M | — | +38.6% |
| EPS (Basic) | -$0.06 | — | +75.0% |
| EPS (Diluted) | -$0.06 | — | +75.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $61.3M | +102.5% | +322.9% |
| Current Assets | $62.3M | +100.6% | +284.0% |
| Total Assets | $63.1M | +97.8% | +277.1% |
| Current Liabilities | $3.3M | +14.0% | -44.3% |
| Total Liabilities | $3.6M | +9.3% | -41.5% |
| Stockholders' Equity | $59.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.3M | — | +47.3% |
| Capital Expenditures | $3K | — | -25.0% |
| Investing Cash Flow | -$3K | — | -100.1% |
| Financing Cash Flow | $35.3M | — | — |
| Free Cash Flow | -$4.3M | — | +47.3% |
| +462.4% |